ParkinsonCanadaV1, Main, Exploration, bibRecord, 003076

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias

Identifieur interne : 003076 ( Main/Exploration ); précédent : 003075; suivant : 003077

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias

Auteurs : Frédéric Calon [Canada] ; Sam Birdi [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada]

Source :

Journal of neuropathology and experimental neurology [ 0022-3069 ] ; 2002.

RBID : Pascal:02-0190928

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Dyskinésie, Toxicité, Système nerveux central, Lévodopa, Immunohistochimie, Hybridation, In situ, Analyse biochimique, Préproenképhaline, Pathogénie, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Age Factors, Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Biochemical analysis, Caudate Nucleus (metabolism), Central nervous system, Dyskinesia, Dyskinesia, Drug-Induced (metabolism), Enkephalins (genetics), Enkephalins (metabolism), Human, Humans, Hybridization, Immunohistochemistry, In Situ Hybridization, In situ, Levodopa, Levodopa (adverse effects), Levodopa (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson disease, Pathogenesis, Preproenkephalin, Protein Precursors (genetics), Protein Precursors (metabolism), Putamen (metabolism), RNA, Messenger (metabolism), Statistics as Topic, Toxicity.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , genetics : Enkephalins, Protein Precursors.
- chemical , metabolism : Enkephalins, Protein Precursors, RNA, Messenger.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- metabolism : Caudate Nucleus, Dyskinesia, Drug-Induced, Parkinson Disease, Putamen.
- Age Factors, Aged, Aged, 80 and over, Humans, In Situ Hybridization, Statistics as Topic.

Abstract

The expression of preproenkephalin messenger RNA was studied in the hrain of Parkinson disease (PD) patients using in situ hybridization. All these patients were treated with levodopa (LD) and the development of motor complications was recorded. Eleven normal controls and 14 PD patients were used, of which 4 developed dyskinesias, 3 developed wearing-off, 3 developed both dyskinesias and wearing-off, and 4 developed no adverse effect following dopaminomimetic therapy. Nigrostriatal denervation was similar between the subgroups of PD patients as assessed using ¹²⁵I-RTI-specific binding to the dopamine transporter and measures of catecholamine concentrations by HPLC. A significant increase of preproenkephalin messenger RNA levels was observed in the lateral putamen of dyskinetic patients in comparison to controls (+210%; p < 0.01) and in comparison to nondyskinetic patients (+112%; p < 0.05). No change was observed in medial parts of the putamen or in the caudate nucleus. No relationship between preproenkephalin messenger RNA levels and other clinical variables such as development of wearing-off, age of death, duration of disease, or duration of LD therapy was found. These findings suggest that increase synthesis of preproenkephalin in the medium spiny output neurons of the striatopallidal pathway play a role in the development of dyskinesias following long-term LD therapy in Parkinson disease.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias</title>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL)</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, Qc</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, Qc</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Birdi, Sam" sort="Birdi, Sam" uniqKey="Birdi S" first="Sam" last="Birdi">Sam Birdi</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon, Sk</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon, Sk</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon, Sk</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon, Sk</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon, Sk</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon, Sk</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Institute for Brain Research, Faculty of Medicine, University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, Qc.</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, Qc.</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Medicine, Laval University</s1>
<s2>Québec, Qc</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, Qc</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL)</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, Qc</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, Qc</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0190928</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0190928 INIST</idno>
<idno type="RBID">Pascal:02-0190928</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B96</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000127</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000A13</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000A13</idno>
<idno type="wicri:doubleKey">0022-3069:2002:Calon F:increase:of:preproenkephalin</idno>
<idno type="wicri:Area/Main/Merge">003522</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11853020</idno>
<idno type="wicri:Area/PubMed/Corpus">001533</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001533</idno>
<idno type="wicri:Area/PubMed/Curation">001533</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001533</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001533</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001533</idno>
<idno type="wicri:Area/Ncbi/Merge">000203</idno>
<idno type="wicri:Area/Ncbi/Curation">000203</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000203</idno>
<idno type="wicri:doubleKey">0022-3069:2002:Calon F:increase:of:preproenkephalin</idno>
<idno type="wicri:Area/Main/Merge">003399</idno>
<idno type="wicri:Area/Main/Curation">003076</idno>
<idno type="wicri:Area/Main/Exploration">003076</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias</title>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL)</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, Qc</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, Qc</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Birdi, Sam" sort="Birdi, Sam" uniqKey="Birdi S" first="Sam" last="Birdi">Sam Birdi</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon, Sk</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon, Sk</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon, Sk</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon, Sk</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon, Sk</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon, Sk</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Institute for Brain Research, Faculty of Medicine, University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Neuroscience Research Unit, Laval University Medical Center (CHUL)</s1>
<s2>Québec, Qc.</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, Qc.</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Medicine, Laval University</s1>
<s2>Québec, Qc</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, Qc</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Oncology and Molecular Endocrinology Research Center, Laval University Medical Center (CHUL)</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Québec, Qc</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Québec, Qc</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of neuropathology and experimental neurology</title>
<title level="j" type="abbreviated">J. neuropathol. exp. neurol.</title>
<idno type="ISSN">0022-3069</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of neuropathology and experimental neurology</title>
<title level="j" type="abbreviated">J. neuropathol. exp. neurol.</title>
<idno type="ISSN">0022-3069</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Biochemical analysis</term>
<term>Caudate Nucleus (metabolism)</term>
<term>Central nervous system</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (metabolism)</term>
<term>Enkephalins (genetics)</term>
<term>Enkephalins (metabolism)</term>
<term>Human</term>
<term>Humans</term>
<term>Hybridization</term>
<term>Immunohistochemistry</term>
<term>In Situ Hybridization</term>
<term>In situ</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson disease</term>
<term>Pathogenesis</term>
<term>Preproenkephalin</term>
<term>Protein Precursors (genetics)</term>
<term>Protein Precursors (metabolism)</term>
<term>Putamen (metabolism)</term>
<term>RNA, Messenger (metabolism)</term>
<term>Statistics as Topic</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Enkephalins</term>
<term>Protein Precursors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Enkephalins</term>
<term>Protein Precursors</term>
<term>RNA, Messenger</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Caudate Nucleus</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
<term>Putamen</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Humans</term>
<term>In Situ Hybridization</term>
<term>Statistics as Topic</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Dyskinésie</term>
<term>Toxicité</term>
<term>Système nerveux central</term>
<term>Lévodopa</term>
<term>Immunohistochimie</term>
<term>Hybridation</term>
<term>In situ</term>
<term>Analyse biochimique</term>
<term>Préproenképhaline</term>
<term>Pathogénie</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The expression of preproenkephalin messenger RNA was studied in the hrain of Parkinson disease (PD) patients using in situ hybridization. All these patients were treated with levodopa (LD) and the development of motor complications was recorded. Eleven normal controls and 14 PD patients were used, of which 4 developed dyskinesias, 3 developed wearing-off, 3 developed both dyskinesias and wearing-off, and 4 developed no adverse effect following dopaminomimetic therapy. Nigrostriatal denervation was similar between the subgroups of PD patients as assessed using <sup>125</sup>
I-RTI-specific binding to the dopamine transporter and measures of catecholamine concentrations by HPLC. A significant increase of preproenkephalin messenger RNA levels was observed in the lateral putamen of dyskinetic patients in comparison to controls (+210%; p < 0.01) and in comparison to nondyskinetic patients (+112%; p < 0.05). No change was observed in medial parts of the putamen or in the caudate nucleus. No relationship between preproenkephalin messenger RNA levels and other clinical variables such as development of wearing-off, age of death, duration of disease, or duration of LD therapy was found. These findings suggest that increase synthesis of preproenkephalin in the medium spiny output neurons of the striatopallidal pathway play a role in the development of dyskinesias following long-term LD therapy in Parkinson disease.</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
<li>Canada</li>
</country>
<region><li>Vienne (Autriche)</li>
</region>
<settlement><li>Vienne (Autriche)</li>
</settlement>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
</noRegion>
<name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name>
<name sortKey="Birdi, Sam" sort="Birdi, Sam" uniqKey="Birdi S" first="Sam" last="Birdi">Sam Birdi</name>
<name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name>
<name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name>
<name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
</country>
<country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Hornykiewicz, Oleh" sort="Hornykiewicz, Oleh" uniqKey="Hornykiewicz O" first="Oleh" last="Hornykiewicz">Oleh Hornykiewicz</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003076 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003076 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:02-0190928
   |texte=   Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.